DEC 06, 2018 07:00 AM PST

Image-based screening for precision medicine and immunotherapy

SPONSORED BY: PerkinElmer
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • CSO and Scientific Co-founder, Allcyte GmbH
    Biography
      Gregory Vladimer is the CSO and a scientific co-founder of Allcyte in Vienna, Austria, where high-throughput and high-content confocal microscopy of primary patient samples is used in order to define drug action at single cell resolution. Dr. Vladimer received his PhD in immunology from the Program in Innate Immunity of the Department of Medicine at the University of Massachusetts Medical School, prior to his postdoctoral work at the Center for Molecular Medicine, CeMM, of the Austrian Academy of Sciences. Dr. Vladimer and his colleagues performed what they believe was the first prospective study assessing the feasibility and efficacy of ex vivo drug-response profiling to guide personalised treatment selection across large panels of possible treatments for patients suffering aggressive haematological malignancies, published at the interim stage last year in Lancet Haematology. The methodology for the screening was invented by a team of scientists who met at CeMM including Prof. Dr. Berend Snijder, Dr. Nikolaus Krall, and Prof. Dr. Giulio Superti-Furga. The team is now focused on determining the feasibility of deploying such image-based single-cell screening assays into the clinical realm for patients with various malignancies. Dr. Vladimer has received numerous grants and fellowships on his work and has publications in NEJM, Nature, Immunity, Cell, Science, Nature Chemical Biology, PNAS, amongst others.

    Abstract:

    DATE: December 06, 2018
    TIME: 15:00 GMT, 16:00 CET, 10:00 EST, 07:00 PST

    High-throughput confocal microscopy has changed the way drug screening can be performed, by enabling the detection of single-cell phenotypes after small molecule or biological perturbation. Combined with advances in image analysis, which have allowed for the quantification of these single cell events, it opens new doors for large phenotype-focused studies. However, these technologies have historically been used with adherent cell lines. By amending these technologies to non-adherent cells, we can perform image-based screening directly in primary material, enabling more clinically translatable drug screening, and ultimately, functional precision medicine. An ongoing clinical trial, from the Center of Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna, combined multiparametric immunofluorescence with high-throughput automated microscopy and single cell image analysis, to quantify tumor-cell specific biological parameters of millions of adherent and non-adherent individual cells from primary samples to prioritize treatment options for patients with late-stage hematological malignancies. An interim analysis revealed that patients receiving treatment prioritized by this program had a longer progression-free survival on this therapy than the prior round of therapy. This style screening can be further combined with epigenetic screening to rationally uncover combination treatment options for specific indications. Lastly, using images of multi-lineage cells from the haematological system, and novel statistical algorithms, we can quantify the propensity of cells to physically interact with each other, thereby mapping the effect of ex vivo stimuli on immune responses, and potentially uncover new immunomodulatory drugs.

    Learning Objectives:

    • How functional precision medicine can be enabled through single-cell image based screening of malignant patient material,
    • How the combination of functional screening through high-throughput imaging and genetics can reveal clinically relevant drug combinations that may be missed by using single-screening approaches,
    • How mapping physical immune responses through cell-to-cell contacts revealed in images can show unknown mechanisms of drugs.

    Show Resources
    You May Also Like
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    NOV 18, 2019 08:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 08:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 8:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    Loading Comments...
    Show Resources